Johnson & Johnson's Q2 earnings to be $2.65 per share, full fiscal year outlook positive.

From Yahoo Finance: 2025-06-27 05:38:00

Johnson & Johnson, based in New Brunswick, NJ, is a healthcare company with a market cap of $366.4 billion. Analysts predict a non-GAAP earnings of $2.65 per share for Q2, a 6% decrease from the previous year. Full fiscal year 2025 earnings expected at $10.60 per share, up 6.2%, and fiscal 2026 at $10.98 per share, up 3.6%.

JNJ stock grew 3.5% in the past 52 weeks, outperforming XLV’s 8.1% decline but lagging behind S&P 500’s 12.1% increase. Despite a dip after Q1 results, JNJ saw 2.4% revenue growth to $21.9 billion, exceeding estimates. Adjusted EPS rose 2.2% to $2.77, with free cash flows up 19.3%.

Analysts give JNJ a “Moderate Buy” rating, with a mean price target of $169.14, suggesting an 11.3% upside potential. Of 23 analysts, nine rate it as “Strong Buy,” two as “Moderate Buy,” and 12 as “Hold.” JNJ stock initially dipped after Q1 results but rebounded over the next two trading sessions.



Read more at Yahoo Finance: Here’s What to Expect From Johnson & Johnson’s Next Earnings Report